Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market

Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet